MedTrace Logo

Effectiveness of Peri-operative Combined Use of 2 Doses of Dexamethasone With Tranexamic Acid in Lower Limb Joint Replacements-A Randomized Controlled Trial.

NCT06653699 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-09-22

No results posted yet for this study

Summary

The goal of this randomized controlled clinical trial is to investigate the effectiveness of peri operative use of 2 doses of dexamethasone with tranexamic acid in lower limb replacement, on post operative C-reactive protein (CRP), joint range of motion, fatigue, pain, hospital length of stay in male/female patients undergoing lower limb joint replacement, with pre op Hb above 10g/dL.

The main question it aims to answer The peri operative use of 2 doses of dexamethasone with tranexamic acid in lower limb replacement, decrease the post operative CRP, fatigue, pain, hospital length of stay and increase the joint range of motion.

Researcher will compare the two groups without knowing which group received either of 1 or 2 doses of Dexamethasone with TXA peri operatively.

Patients will do answer the questions mentioned in questionnaire pre operatively, at post op 1st day, at 1st week and 4th week post discharge.

Conditions

  • Hip Replacement
  • Knee Replacement

Interventions

DRUG

2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID

In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.

DRUG

1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID

In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.

Sponsors & Collaborators

  • Indus Hospital and Health Network

    lead OTHER

Principal Investigators

  • Zaib Un Nisa, MS IN MSK PHYSIOTHERAPY · Indus Hospital and Health Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-11
Primary Completion
2025-07-03
Completion
2025-07-20

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06653699 on ClinicalTrials.gov